Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Low-molecular-weight heparin for pregnancy complications

Pre-eclampsia, fetal growth restriction, placental abruption, and recurrent miscarriage are common placenta-mediated pregnancy complications. They have overlapping pathological features including deficient placentation, microvascular thrombosis, placental infarction, and an association with thrombophilia,1–3 implicating coagulation activation as a disease mechanism. Antithrombotic treatment has been shown to improve the outcome of antiphospholipid syndrome manifested as recurrent pregnancy loss, and low-dose aspirin provides a modest risk reduction in women with previous pre-eclampsia.